Biopharmaceutical companies spent nearly $165 billion on drug development in 2017.

Source: NIH.gov; Factset, EvaluatePHarma, BIO Industry Analysis, October 2018

GLOBAL PRIVATE SECTOR R&D VS. NIH BUDGET

<table>
<thead>
<tr>
<th>Private Sector</th>
<th>NIH Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>$165B</td>
<td>$33B</td>
</tr>
</tbody>
</table>

2017

About 90% of new drugs originate entirely from industry research.


United States biopharmaceutical companies:

- Reinvest more of their revenue into R&D than any other industry.
- Fund nearly 1/4 of all R&D conducted by U.S. industries.
- Will spend $204B annually on drug development by 2024.
- Paid $1B in royalties to the federal government between 2011 & 2018 to support future basic research.